This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cordero, P. Articles by Hollenberg, N. K. Search for Related Content PubMed PubMed Citation Articles by Cordero, P. Articles by Hollenberg, N. K.

Hypertension, Vol 17, 510-516, Copyright © 1991 by American Heart Association

ARTICLES

Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans

P Cordero, ND Fisher, TJ Moore, R Gleason, GH Williams and NK Hollenberg
Department of Medicine, Harvard Medical School, Boston, Mass.

Interpretation of renin-angiotensin blockade with angiotensin converting enzyme inhibitors is potentially confounded by their multiple effects. We used a selective renin inhibitor (enalkiren, A- 64662) to explore the renal and endocrine effects of angiotensin II in healthy men. Each received 90-minute enalkiren infusions at 2-day intervals, on a low (10 mmol, 16 subjects) and high (200 mmol, 12 subjects) salt diet. Plasma renin activity, immunoreactive plasma angiotensin II and aldosterone concentrations, inulin, and p- aminohippurate clearance were measured by standard methods. Plasma renin activity fell at 0.1 micrograms/kg, but the threshold for biologic effect was 256 micrograms/kg, where plasma immunoreactive angiotensin II and aldosterone concentration fell, and renal plasma flow rose (p less than 0.01). The maximal renal vascular response (+152 +/- 23 ml/min/1.73 m2) occurred at 512 micrograms/kg (p less than 0.01). Diastolic and mean blood pressure fell modestly but significantly (p less than 0.05). Responses were limited on a high salt diet. We confirm that conventional plasma renin activity measurement is misleading in humans receiving a renin inhibitor. The renal vascular response to renin inhibition in this study appeared to substantially exceed reported responses to angiotensin converting enzyme inhibition, perhaps reflecting a crucial and relatively inaccessible intrarenal locus.

This article has been cited by other articles:

				N. D.L. Fisher and N. K. Hollenberg Renin Inhibition: What Are the Therapeutic Opportunities? J. Am. Soc. Nephrol., March 1, 2005; 16(3): 592 - 599. [Abstract] [Full Text] [PDF]

				M. C. Lansang, S. Y. Osei, D. A. Price, N. D. L. Fisher, and N. K. Hollenberg Renal Hemodynamic and Hormonal Responses to the Angiotensin II Antagonist Candesartan Hypertension, November 1, 2000; 36(5): 834 - 838. [Abstract] [Full Text] [PDF]

				P. van Paassen, D. de Zeeuw, G. Navis, and P. E. de Jong Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function Nephrol. Dial. Transplant., May 1, 2000; 15(5): 637 - 643. [Abstract] [Full Text] [PDF]

				N. K. Hollenberg Implications of Species Difference for Clinical Investigation : Studies on the Renin-Angiotensin System Hypertension, January 1, 2000; 35(1): 150 - 154. [Abstract] [Full Text] [PDF]

				N. K. Hollenberg, N. D. L. Fisher, and D. A. Price Pathways for Angiotensin II Generation in Intact Human Tissue : Evidence From Comparative Pharmacological Interruption of the Renin System Hypertension, September 1, 1998; 32(3): 387 - 392. [Abstract] [Full Text] [PDF]

				D. A. Price, J. M. De'Oliveira, N. D. L. Fisher, and N. K. Hollenberg Renal Hemodynamic Response to an Angiotensin II Antagonist, Eprosartan, in Healthy Men Hypertension, August 1, 1997; 30(2): 240 - 246. [Abstract] [Full Text]

				N. K. Hollenberg and N. D. L. Fisher Renal Circulation and Blockade of the Renin-Angiotensin System : Is Angiotensin-Converting Enzyme Inhibition the Last Word? Hypertension, October 1, 1995; 26(4): 602 - 609. [Abstract] [Full Text]

				N. D. L. Fisher, D. R. Allan, C. L. Gaboury, and N. K. Hollenberg Intrarenal Angiotensin II Formation in Humans : Evidence From Renin Inhibition Hypertension, May 1, 1995; 25(5): 935 - 939. [Abstract] [Full Text]